MetabolicEmerging Evidence

Retatrutide

Also known as: Triple agonist, GIP/GLP-1/Glucagon agonist

Investigational triple agonist targeting GIP, GLP-1, and glucagon receptors for maximal metabolic benefit and weight loss.

Benefits

Conditions

Evidence

Phase 2 trials published in NEJM 2023+ studies

Source

Synthetic triple receptor agonist

Gabriel Brain Score

Strong

Overview

Investigational triple agonist targeting GIP, GLP-1, and glucagon receptors for maximal metabolic benefit and weight loss.

Mechanism of Action

Tri-agonist activating GIP, GLP-1, and glucagon receptors simultaneously, enhances insulin secretion and suppresses appetite (GIP/GLP-1), increases energy expenditure and fat oxidation (glucagon), synergistic metabolic optimization across multiple pathways.

Key Benefits

✓Exceptional weight loss (24-27% in trials)
✓Increased energy expenditure
✓Enhanced fat oxidation
✓Appetite suppression
✓Improved glycemic control
✓Metabolic optimization

Clinical Applications

Obesity (investigational)Type 2 diabetes (investigational)Metabolic syndromeWeight management

Dosing Guidelines

Subcutaneous injection

Typical DosePhase 2 trials: 0.5-12 mg

FrequencyOnce weekly

DurationUnder investigation

* Dosing should be individualized. Always consult with a qualified healthcare practitioner.

Research & Evidence

Evidence Level

Emerging

Studies

Phase 2 trials published in NEJM 2023

Summary

Phase 2 trial showed 24% weight loss at 48 weeks (12 mg dose), superior to any approved agent. Excellent tolerability profile. Phase 3 trials ongoing. Represents next frontier in metabolic pharmacotherapy.

Safety Information

Potential Side Effects

•Nausea (dose-dependent)
•Diarrhea
•Vomiting
•Constipation
•Generally well-tolerated in trials

Contraindications

Under investigation
Likely similar to GLP-1 agonists

Interactions

⚠Under investigation

Quick Facts

CategoryMetabolic

SourceSynthetic triple receptor agonist

Legal StatusInvestigational, Phase 3 trials ongoing

Gabriel Brain Score

95/ 100

Source Your Protocol

Our preferred peptide partner offers lab-tested, COA-verified peptides with optional physician oversight. Sourced from US-regulated facilities.

Related Peptides

Tirzepatide

Dual GIP and GLP-1 receptor agonist that produces superior weight loss and glycemic control compared to GLP-1 agonists alone.

StrongLearn more →

Semaglutide

Long-acting GLP-1 receptor agonist that reduces appetite, improves glycemic control, and promotes significant weight loss.

StrongLearn more →

Survodutide

Investigational dual glucagon and GLP-1 receptor agonist for obesity and metabolic dysfunction-associated steatohepatitis (MASH).

EmergingLearn more →